AstraZeneca Reports Five-Year SOLO-2 Data for Lynparza in BRCA-Mutated Ovarian Cancer

AstraZeneca today presented five-year follow-up data from the Phase 3 SOLO-2 trial evaluating Lynparza (olaparib) as maintenance therapy in patients with platinum-sensitive relapsed BRCA-mutated ovarian cancer. The data showed that the progression-free survival benefit of Lynparza was maintained at five years, with a 70% reduction in the risk of disease progression or death.